Use of pro-atrial natriuretic peptide in the detection of myocardial ischaemia

被引:3
|
作者
Bocek, T
Morgenthaler, NG
Staub, D
Nusbaumer, C
Christ, A
Zellweger, MJ
Mueller-Brand, J
Mueller, B
Perruchoud, AP
Mueller, C
机构
[1] Univ Basel Hosp, Med Klin A, Dept Internal Med, Med Div A, CH-4031 Basel, Switzerland
[2] Brahms AG, Berlin, Germany
[3] Univ Basel Hosp, Dept Lab Med, CH-4031 Basel, Switzerland
[4] Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland
[5] Univ Basel Hosp, Div Nucl Med, CH-4031 Basel, Switzerland
[6] Univ Basel Hosp, Clin Endocrinol Diabet & Clin Nutr, CH-4031 Basel, Switzerland
关键词
exercise; ischaemia; natriuretic peptides;
D O I
10.1111/j.1365-2362.2005.01517.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Because of its unique storage and release mechanisms allowing a very rapid response to haemodynamic changes, pro-atrial natriuretic peptide (proANP) may be a helpful cardiac marker in the detection of myocardial ischaemia. Materials and methods A total of 260 consecutive patients with suspected myocardial ischaemia referred for rest/ergometry myocardial perfusion single-photon emission computed tomography (SPECT) were enrolled. Levels of plasma proANP were determined before and 1 min after maximal exercise. Results Baseline proANP and peak exercise proANP were significantly higher in patients with myocardial ischaemia as compared to those without ischaemia (median, 82 [IQR, 57-112] vs. 67 [IQR, 50-106] pmol L-1, P = 0.007; and 89 [IQR, 65-121] vs. 78 [IQR, 57-116] pmol L-1, P = 0.033). The area under the ROC curve for baseline proANP was 0.597 (95% CI, 0.527-0.667), as compared to 0.577 (95% CI, 0.507-0.648) for peak exercise proANP. Exercise-induced changes in proANP were similar in patients with and without myocardial ischaemia, and showed no correlation with the extent of myocardial ischaemia. Conclusions Baseline proANP and peak exercise proANP are significantly higher in patients with myocardial ischaemia. However, because of considerable overlap in proANP levels between patients with and without myocardial ischaemia, neither measurement seems helpful in the detection of myocardial ischaemia in clinical practice.
引用
收藏
页码:450 / 456
页数:7
相关论文
共 50 条
  • [41] MR-pro midregional pro-atrial natriuretic peptide and risk of cardiovascular death in coronary artery disease
    Schnabel, Renate
    Lubos, Edith
    Sinning, Christoph
    Bickel, Christoph
    Rupprecht, Hans J.
    Lackner, Karl J.
    Papassotiriou, J.
    Struck, J.
    Munzel, Thomas F.
    Blankenberg, Stefan
    CIRCULATION, 2007, 116 (16) : 852 - 852
  • [42] N-Terminal Pro-Atrial Natriuretic Peptide Measurement in Plasma Suggests Covalent Modification
    Hunter, Ingrid
    Alehagen, Urban
    Dahlstrom, Ulf
    Rehfeld, Jens F.
    Crimmins, Dan L.
    Goetze, Jens P.
    CLINICAL CHEMISTRY, 2011, 57 (09) : 1327 - 1330
  • [43] Characterization of the corin-mediated pro-atrial natriuretic peptide processing in murine cardiac myocytes
    Wu, F
    Yan, W
    Pan, JL
    Morser, J
    Wu, QY
    CIRCULATION, 2001, 104 (17) : 172 - 173
  • [44] Plasma levels of N-terminal peptide of pro-atrial natriuretic peptides in myoskeletal injuries
    Onuoha, GN
    Alpar, EK
    REGULATORY PEPTIDES, 2001, 99 (01) : 17 - 20
  • [45] Mitregionales Pro-Atrial Natriuretic Peptide (MRpro-ANP) during the postpartural and postnatal Adaptation
    Benzing, J.
    Wellmann, S.
    Szinnai, G.
    Hegi, L.
    Admaty, D.
    Cippa, G.
    Beinder, E.
    Morgenthaler, N.
    Haagen, U.
    Bucher, H. U.
    Buehrer, C.
    Lapaire, O.
    KLINISCHE PADIATRIE, 2010, 222 : S86 - S87
  • [46] Is mid-regional pro-atrial natriuretic peptide (MRproANP) an accurate marker of bacteremia in pyelonephritis?
    Guinard-Barbier, Solweig
    Grabar, Sophie
    Chenevier-Gobeaux, Camille
    Quinquis, Laurent
    Schmidt, Jeannot
    Kierzek, Gerald
    Guerin, Sylvie
    Hausfater, Pierre
    Bernot, Bruno
    Brun, Patrick
    Gayet, Alberic
    Casalino, Enrique
    Andreotti, Christophe
    Renaud, Bertrand
    Claessens, Yann-Erick
    BIOMARKERS, 2011, 16 (04) : 355 - 363
  • [47] Plasma mid-regional pro-atrial natriuretic peptide is associated with and improves prediction of lone atrial fibrillation
    Chen, L. Y.
    Chong, J. P.
    Chang, I. C.
    Austin, E.
    Quay, C. N.
    Richards, A. M.
    Ling, L. H.
    EUROPEAN HEART JOURNAL, 2013, 34 : 738 - 738
  • [48] Usefulness of mid regional pro-atrial natriuretic peptide in the exacerbations of chronic obstructive pulmonary disease
    Lacoma, Alicia
    Prat, Cristina
    Andreo, Felipe
    Lores, Luis
    Latorre, Irene
    Perez, Miguel
    Ruiz-Manzano, Juan
    Ausina, Vicente
    Dominguez, Jose
    CLINICA CHIMICA ACTA, 2011, 412 (5-6) : 470 - 475
  • [49] Pro-Atrial Natriuretic Peptide In Vitro and In Vivo Normal Canines: A Selective Renal Enhancing Therapeutic
    Ichiki, Tomoko
    Ingrid, Anderson A.
    Huntley, Brenda K.
    Sangaralingham, S. Jeson
    Harty, Gail J.
    Sandberg, Sharon M.
    Heublein, Denise M.
    Burnett, John C., Jr.
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (08) : S27 - S27
  • [50] Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea
    Eckstein, Jens
    Potocki, Mihael
    Murray, Karsten
    Breidthardt, Tobias
    Ziller, Ronny
    Mosimann, Tamina
    Klima, Theresia
    Hoeller, Rebeca
    Moehring, Berit
    Sou, Seoung Mann
    Gimenez, Maria Rubini
    Morgenthaler, Nils G.
    Mueller, Christian
    HEART, 2012, 98 (20) : 1518 - 1522